HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adrenocortical carcinoma: a clinician's update.

Abstract
Adrenocortical carcinoma is a rare heterogeneous neoplasm with an incompletely understood pathogenesis and a poor prognosis. Previous studies have identified overexpression of insulin-like growth factor 2 (IGF-2) and constitutive activation of β-catenin as key factors involved in the development of adrenocortical carcinoma. Most patients present with steroid hormone excess, for example Cushing syndrome or virilization, or abdominal mass effects, but a growing proportion of patients with adrenocortical carcinoma (currently >15%) is initially diagnosed incidentally. No general consensus on the diagnostic and therapeutic measures for adrenocortical carcinoma exists, but collaborative efforts, such as international conferences and networks, including the European Network for the Study of Adrenal Tumors (ENSAT), have substantially advanced the field. In patients with suspected adrenocortical carcinoma, a thorough endocrine and imaging work-up is recommended to guide the surgical approach aimed at complete resection of the tumor. To establish an adequate basis for treatment decisions, pathology reports include the Weiss score to assess malignancy, the resection status and the Ki67 index. As recurrence is frequent, close follow-up initially every 3 months is mandatory. Most patients benefit from adjuvant mitotane treatment. In metastatic disease, mitotane is the cornerstone of initial treatment, and cytotoxic drugs should be added in case of progression. Results of a large phase III trial in advanced adrenocortical carcinoma are anticipated for 2011 and will hopefully establish a benchmark therapy. New targeted therapies, for example, IGF-1 receptor inhibitors, are under investigation and may soon improve current treatment options.
AuthorsMartin Fassnacht, Rossella Libé, Matthias Kroiss, Bruno Allolio
JournalNature reviews. Endocrinology (Nat Rev Endocrinol) Vol. 7 Issue 6 Pg. 323-35 (Jun 2011) ISSN: 1759-5037 [Electronic] England
PMID21386792 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Topics
  • Adrenal Cortex Neoplasms (diagnosis, etiology, genetics, therapy)
  • Adrenocortical Carcinoma (diagnosis, etiology, genetics, therapy)
  • Algorithms
  • Clinical Laboratory Techniques (trends)
  • Education, Medical, Continuing
  • Endocrinology (education, trends)
  • Genes, Tumor Suppressor (physiology)
  • Humans
  • Models, Biological
  • Oncogenes (genetics, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: